Copyright
©The Author(s) 2016.
World J Hepatol. Jan 28, 2016; 8(3): 139-147
Published online Jan 28, 2016. doi: 10.4254/wjh.v8.i3.139
Published online Jan 28, 2016. doi: 10.4254/wjh.v8.i3.139
Table 3 Overview on clinical studies using the combination of paritaprevir/ritonavir + ombitasvir ± dasabuvir
| Study | Patient population | Therapy | Duration (wk) | SVR | Comments |
| SAPPHIRE-I | First-line therapy | OBV + PTV/r + DSV + R | 12 | 96% | No cirrhosis |
| SAPPHIRE-II | Re-therapy | OBV + PTV/r + DSV + R | 12 | 96% | No cirrhosis |
| TURQUOISE-II | Cirrhosis | OBV + PTV/r + DSV + R | 12 | 92% | GT1a 89% |
| GT1b 99% | |||||
| OBV + PTV/r + DSV + R | 24 | 96% | GT1a 95% | ||
| GT1b 100% | |||||
| PEARL-II | Re-therapy, GT1b | OBV + PTV/r + DSV | 12 | 100% | No cirrhosis |
| OBV + PTV/r + DSV + R | 12 | 97% | No cirrhosis | ||
| PEARL-III | First-line therapy, GT1b | OBV + PTV/r + DSV | 12 | 99% | No cirrhosis |
| OBV + PTV/r + DSV + R | 12 | 99% | No cirrhosis | ||
| PEARL-IV | First-line therapy, GT1a | OBV + PTV/r + DSV | 12 | 90% | No cirrhosis |
| OBV + PTV/r + DSV + R | 12 | 97% | No cirrhosis |
- Citation: Zopf S, Kremer AE, Neurath MF, Siebler J. Advances in hepatitis C therapy: What is the current state - what come’s next? World J Hepatol 2016; 8(3): 139-147
- URL: https://www.wjgnet.com/1948-5182/full/v8/i3/139.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i3.139